載入中
Kala Bio, Inc. functions as a biopharmaceutical company dedicated to the creation and commercialization of new therapeutic solutions. The core of their strategy involves utilizing proprietary nanoparticle technology, specifically mucus penetrating particles (MPPs). Initially, their focus for these treatments is directed towards ophthalmic diseases. The company was established in 2009 by co-founders Justin Hanes, Robert S. Langer, and Colin R. Gardner, and its headquarters are located in Arlington, Massachusetts.
前收盤價
US$0.28
−US$0.014 · -4.76%
盤後
US$0.2834
+US$0.0034 · +1.21%
10月12日 下午7:30 ET
盤中時間採用ET。市場資料可能有所延遲。
Kala Bio, Inc. functions as a biopharmaceutical company dedicated to the creation and commercialization of new therapeutic solutions. The core of their strategy involves utilizing proprietary nanoparticle technology, specifically mucus penetrating particles (MPPs). Initially, their focus for these treatments is directed towards ophthalmic diseases. The company was established in 2009 by co-founders Justin Hanes, Robert S. Langer, and Colin R. Gardner, and its headquarters are located in Arlington, Massachusetts.
日內區間
目前US$0.28
52週區間
目前US$0.28
盤中時間採用ET。市場資料可能有所延遲。
Kala Bio, Inc. functions as a biopharmaceutical company dedicated to the creation and commercialization of new therapeutic solutions. The core of their strategy involves utilizing proprietary nanoparticle technology, specifically mucus penetrating particles (MPPs). Initially, their focus for these treatments is directed towards ophthalmic diseases. The company was established in 2009 by co-founders Justin Hanes, Robert S. Langer, and Colin R. Gardner, and its headquarters are located in Arlington, Massachusetts.
日內區間
目前US$0.28
52週區間
目前US$0.28
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | — | — | — | 389.2萬 USD | 1124萬 USD |
| 銷貨成本 | — | 25.9萬 USD | 30.3萬 USD | 256萬 USD | 409.7萬 USD |
| 毛利 | — | −25.9萬 USD | −30.3萬 USD | 133.2萬 USD | 714.3萬 USD |
| 研究與開發 | 1878萬 USD | 2183.5萬 USD | 1858.6萬 USD | 1765.3萬 USD | 1151.5萬 USD |
| 銷售、一般及管理費用 | 2362.9萬 USD | 1834萬 USD | 2026.4萬 USD | 6503.5萬 USD | 1.05億 USD |
| 營業費用 | 3916.1萬 USD | 4017.5萬 USD | 3885萬 USD | 8268.8萬 USD | 1.17億 USD |
| 利息收入 | 114萬 USD | 205.6萬 USD | 271.1萬 USD | 66.4萬 USD | 10.4萬 USD |
| 利息支出 | 327.6萬 USD | 578.3萬 USD | 581.4萬 USD | 726.6萬 USD | 838萬 USD |
| 折舊和攤銷 | 31.7萬 USD | 25.9萬 USD | 30.3萬 USD | 53.7萬 USD | 97.5萬 USD |
| 營業利益 | −3916.1萬 USD | −4043.4萬 USD | −3915.3萬 USD | −8135.6萬 USD | −1.09億 USD |
| 淨利 | −2698萬 USD | −3851.1萬 USD | −4219.9萬 USD | −4482.2萬 USD | −1.43億 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$18.25
上漲空間 6417.86%| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2026年5月11日 | 1:50 | — | — |
股票分割 | 2022年10月21日 | 1:50 | — | — |
股票分割 | 2022年8月26日 | 2:1 | — | — |
已生效 2026年5月11日
1:50
已生效 2022年10月21日
1:50
已生效 2022年8月26日
2:1
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
